Neuropace Stock Market Value
| NPCE Stock | USD 10.60 0.35 3.41% |
| Symbol | Neuropace |
Neuropace Price To Book Ratio
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neuropace. If investors know Neuropace will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neuropace listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.98) | Revenue Per Share 2.697 | Quarterly Revenue Growth 0.282 | Return On Assets (0.15) | Return On Equity (2.15) |
The market value of Neuropace is measured differently than its book value, which is the value of Neuropace that is recorded on the company's balance sheet. Investors also form their own opinion of Neuropace's value that differs from its market value or its book value, called intrinsic value, which is Neuropace's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neuropace's market value can be influenced by many factors that don't directly affect Neuropace's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neuropace's value and its price as these two are different measures arrived at by different means. Investors typically determine if Neuropace is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuropace's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Neuropace 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Neuropace's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Neuropace.
| 06/03/2024 |
| 11/30/2024 |
If you would invest 0.00 in Neuropace on June 3, 2024 and sell it all today you would earn a total of 0.00 from holding Neuropace or generate 0.0% return on investment in Neuropace over 180 days. Neuropace is related to or competes with Electromed, Orthopediatrics Corp, SurModics, Paragon 28, Nevro Corp, Integer Holdings, and Glaukos Corp. NeuroPace, Inc. operates as a medical device company in the United States More
Neuropace Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Neuropace's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Neuropace upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.53 | |||
| Information Ratio | 0.0893 | |||
| Maximum Drawdown | 35.38 | |||
| Value At Risk | (6.19) | |||
| Potential Upside | 9.73 |
Neuropace Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Neuropace's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Neuropace's standard deviation. In reality, there are many statistical measures that can use Neuropace historical prices to predict the future Neuropace's volatility.| Risk Adjusted Performance | 0.0967 | |||
| Jensen Alpha | 0.3049 | |||
| Total Risk Alpha | (0.28) | |||
| Sortino Ratio | 0.1343 | |||
| Treynor Ratio | 0.2585 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Neuropace's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Neuropace Backtested Returns
Neuropace appears to be moderately volatile, given 3 months investment horizon. Neuropace has Sharpe Ratio of 0.13, which conveys that the firm had a 0.13% return per unit of risk over the last 3 months. By analyzing Neuropace's technical indicators, you can evaluate if the expected return of 0.7% is justified by implied risk. Please exercise Neuropace's Downside Deviation of 3.53, risk adjusted performance of 0.0967, and Mean Deviation of 3.44 to check out if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Neuropace holds a performance score of 10. The company secures a Beta (Market Risk) of 2.33, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Neuropace will likely underperform. Please check Neuropace's value at risk, kurtosis, price action indicator, as well as the relationship between the semi variance and rate of daily change , to make a quick decision on whether Neuropace's current price movements will revert.
Auto-correlation | 0.11 |
Insignificant predictability
Neuropace has insignificant predictability. Overlapping area represents the amount of predictability between Neuropace time series from 3rd of June 2024 to 1st of September 2024 and 1st of September 2024 to 30th of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Neuropace price movement. The serial correlation of 0.11 indicates that less than 11.0% of current Neuropace price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.11 | |
| Spearman Rank Test | 0.1 | |
| Residual Average | 0.0 | |
| Price Variance | 1.46 |
Neuropace lagged returns against current returns
Autocorrelation, which is Neuropace stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Neuropace's stock expected returns. We can calculate the autocorrelation of Neuropace returns to help us make a trade decision. For example, suppose you find that Neuropace has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Neuropace regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Neuropace stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Neuropace stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Neuropace stock over time.
Current vs Lagged Prices |
| Timeline |
Neuropace Lagged Returns
When evaluating Neuropace's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Neuropace stock have on its future price. Neuropace autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Neuropace autocorrelation shows the relationship between Neuropace stock current value and its past values and can show if there is a momentum factor associated with investing in Neuropace.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Neuropace is a strong investment it is important to analyze Neuropace's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Neuropace's future performance. For an informed investment choice regarding Neuropace Stock, refer to the following important reports:Check out Neuropace Correlation, Neuropace Volatility and Neuropace Alpha and Beta module to complement your research on Neuropace. For information on how to trade Neuropace Stock refer to our How to Trade Neuropace Stock guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Neuropace technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.